Haleon PLC (GB:HLN)
LSE:HLN
Want to see GB:HLN full AI Analyst Report?
HLN Stock Chart & Stats
353.10 p
2.70 p(0.71%)
At close: 4:00 PM EST
353.10 p
2.70 p(0.71%)
Day’s Range― - ―
52-Week Range274.40 p - 419.50 p
Previous CloseN/A
Volume4.86M
Average Volume (3M)23.77M
Market Cap
£31.45B
Enterprise Value38.68B
Total Cash (Recent Filing)£676.00M
Total Debt (Recent Filing)£8.54B
Price to Earnings (P/E)20.1
Beta0.38
Next Earnings
Jul 30, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend Yield1.51%
Share Statistics
EPS (TTM)0.05
Shares Outstanding8,907,384,000
10 Day Avg. Volume25,018,353
30 Day Avg. Volume23,772,072
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio16.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£435.91Price Target Upside23.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.21
Revenue Forecast (FY)£11.40B
Bulls Say, Bears Say
Bulls Say
Cold And Flu DemandAnalyst notes that an increase in US cold and flu demand is boosting product sales and supporting a broader recovery in headline growth.
Core Business MomentumAnalyst points to underlying sales growth excluding cold and flu and improving momentum in the United States and emerging markets as evidence of core business resilience and upside potential.
Margins And Earnings ResilienceAnalyst highlights margin improvement and supportive operating profit guidance that can sustain earnings per share and provide protection while top-line growth normalizes.
Bears Say
Emerging Markets WeaknessAnalyst warns that persistent weak consumer trends in markets such as Brazil and muted demand in parts of Europe are weighing on sales and mean emerging market growth must accelerate to justify the investment case.
Inventory And Guidance RiskAnalyst flags ongoing inventory destocking in North America combined with softer medium-term sales guidance, which could restrain near-term volume growth and put pressure on valuation if reinvestment needs rise.
Sales Shortfall And DisclosureAnalyst describes a significant cold and flu sales shortfall that weighed on reported results and criticizes weak communication around the shortfall, contributing to stock underperformance.
Haleon PLC News
HLN FAQ
What was Haleon PLC’s price range in the past 12 months?
Haleon PLC lowest share price was 274.40 p and its highest was 419.50 p in the past 12 months.
What is Haleon PLC’s market cap?
Haleon PLC’s market cap is £31.45B.
When is Haleon PLC’s upcoming earnings report date?
Haleon PLC’s upcoming earnings report date is Jul 30, 2026 which is in 104 days.
How were Haleon PLC’s earnings last quarter?
Haleon PLC released its earnings results on Feb 25, 2026. The company reported 0.048 p earnings per share for the quarter, beating the consensus estimate of 0.046 p by 0.002 p.
Is Haleon PLC overvalued?
According to Wall Street analysts Haleon PLC’s price is currently Undervalued.
Does Haleon PLC pay dividends?
Haleon PLC pays a Quarterly dividend of 2.2 p which represents an annual dividend yield of 1.51%. See more information on Haleon PLC dividends here
What is Haleon PLC’s EPS estimate?
Haleon PLC’s EPS estimate is 0.1.
How many shares outstanding does Haleon PLC have?
Haleon PLC has 8,907,384,000 shares outstanding.
What happened to Haleon PLC’s price movement after its last earnings report?
Haleon PLC reported an EPS of 0.048 p in its last earnings report, beating expectations of 0.046 p. Following the earnings report the stock price went down -6.852%.
Which hedge fund is a major shareholder of Haleon PLC?
Currently, no hedge funds are holding shares in GB:HLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£435.91 (23.45% Upside)
£435.91 (23.45% Upside)
Blogger Sentiment
Bullish
GB:HLN Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth £2.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.91%
12-Months-Change
Fundamentals
Return on Equity
6.43%
Trailing 12-Months
Asset Growth
-4.91%
Trailing 12-Months
Company Description
Haleon PLC
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
HLN Stock 12 Month Forecast
Average Price Target
435.91 p
▲(23.45% Upside)
Technical Analysis
Allergy Therapeutics
―
Provexis
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---